Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Extragonadal Germ Cell Tumors Follow-up

  • Author: Kush Sachdeva, MD; Chief Editor: Jules E Harris, MD, FACP, FRCPC  more...
 
Updated: Apr 16, 2015
 

Further Outpatient Care

See the list below:

  • Detection of late recurrences (>2 y after treatment discontinuation), development of testicular tumors several years after the initial diagnosis of extragonadal germ cell tumors (EGGCTs), and treatment-related complications justify prolonged periods of follow-up care with clinical evaluation, tumor markers, and imaging studies.
  • In children (and probably in adults) with intracranial germ cell tumors (ICGCTs), obtain baseline intelligence quotient (IQ) and achievement tests before starting radiotherapy. Perform follow-up intellectual assessments at 1 year after completion of radiation, then at 2, 3, and 5 years, and if any intellectual deterioration is noted. Evaluate hearing if intellectual deterioration occurs. Evaluation of thyroid, corticotropin, gonadotropin, prolactin, and GH functions is obtained before and regularly after radiation therapy.
Next

Complications

See the list below:

  • Growing teratoma syndrome is the increase in tumor size during or after chemotherapy for mediastinal germ cell tumors (MGCT) or retroperitoneal germ cell tumors (RGCT) and only mature teratoma at histologic analysis of the resected tumor specimen.[25] Mature teratoma component is present in the majority of the primary tumors (86%). The major risk factor for this complication is the completeness of the surgical resection of the primary tumor because it was seen in only 4% of the patients who underwent complete resection compared to 83% of those patients who had partial resection. Complete surgical resection is the treatment of choice.
  • Rupture of a mature teratoma as a result of the digestive enzymes secreted by intestinal mucosa or pancreatic tissue into the bronchi or lung may result in hemoptysis[26] or expectoration of hair or sebum. Rupture into the pleura or pericardium leads to pericardial or pleural effusion.
  • Teratoma with malignant transformation is a rare complication of mediastinal germ cell tumors. The most common transformations are different kinds of sarcomas, glioblastomas, nephroblastomas, neuroblastomas, adenocarcinomas, and hematologic malignancies.
  • The incidence of hematologic malignancies in patients with nonseminomatous mediastinal germ cell tumors (NS-MGCTs) is 200- to 300-fold higher than in matched controls.
    • The median time from the diagnosis of the germ cell tumors (GCTs) to the diagnosis of the hematologic malignancy is 6 months (range 0-47 mo). Acute myelogenous leukemia and myelodysplasia with megakaryocyte lineage abnormalities are the most common disorders.
    • Patients present with pancytopenia, isolated thrombocytopenia, splenomegaly, and/or hepatomegaly. Flushing and syncope are suggestive of systemic mastocytosis, another unusual hematologic malignancy complicating mediastinal germ cell tumors.
    • The clinical course is very aggressive, with a median survival of 5 months. Predictors of the subsequent occurrence of leukemia are mediastinal localization of the germ cell tumors and endodermal sinus tumor and teratocarcinoma histologic types. Bone marrow biopsy should not be delayed if cytopenia persists or recurs after the initial chemotherapy period.
  • Chemotherapy-related complications may be immediate or delayed.
    • Nausea and vomiting became less common with the advent of 5-hydroxytryptamine 3 (5-HT3) antagonists. Postcisplatin delayed emesis is better treated by oral administration of metoclopramide, benzodiazepine, and dexamethasone for 2-4 days.
    • A certain degree of cisplatin-related nephrotoxicity is almost always present and is cumulative. Hypomagnesemia is common, requiring supplementation for prolonged periods in some patients.
    • Arthralgias, myalgias, peripheral neuropathy, and paralytic ileus are common toxic effects of vinblastine. However, since replacement of vinblastine with etoposide in first-line therapy began, these complications are no longer seen. Auditory toxicity with reduced high-tone hearing may be seen after cisplatin. It rarely requires hearing aids.
    • Neutropenic fever and severe thrombocytopenia are relatively uncommon with etoposide and cisplatin (EP) as first-line chemotherapy. The addition of bleomycin and salvage chemotherapy results in significant increase of these complications (50%), requiring the prophylactic use of hematopoietic growth factors after the first episode of neutropenic fever.
    • Pulmonary toxicity from bleomycin is unpredictable and rare (10% of treated patients) and is dose- and age-dependent (rate is higher in patients >70 y and after a cumulative dose >1200 IU or 400 mg). The progression to pulmonary fibrosis is uncommon and occasionally fatal (1%). Although carbon monoxide diffusing capacity may not predict clinically significant lung damage, its use was recommended along with chest x-ray as a screening test in patients treated with bleomycin. If radiographic changes or a decrease of diffusing capacity of lung for carbon monoxide (DLCO) greater than 30% is detected, discontinue the drug.
    • Raynaud phenomenon and, to a lesser degree, stroke and myocardial infarction were reported after use of bleomycin.
    • Accelerated coronary artery disease is a well-recognized complication of mediastinal radiotherapy.
    • Infertility is seen in as many as 50% of patients after chemotherapy. Standard bilateral retroperitoneal lymph node dissection almost always is associated with retrograde ejaculation. Nerve-dissecting, nerve-avoiding, and posterior approaches decrease, but do not abolish, this adverse effect.
    • The frequency of etoposide-related secondary leukemia is dose dependent. It is seen in less than 0.5% of patients who received a total dose less than 2000 mg/m2 and in about 6% of those who received more than 3000 mg/m2. Abnormalities of chromosome band 11q23 are very common in this setting. Latency period varies from 2-4 years. The incidence of gastrointestinal malignancies, especially gastric cancers, and soft-tissue sarcomas is increased slightly after combined radiation and chemotherapy. Latency period is about 10 years or more.
    • Weijl et al reported a high rate of thromboembolic events (8.4%) during chemotherapy in 179 patients with germ cell tumors. Liver metastases and high-dose corticosteroids were identified as risk factors for these complications.[27]
  • With the achievement of prolonged survival for patients with intracranial germ cell tumors (ICGCTs), researchers became increasingly aware of long-term effects of cranial radiation on intellectual and endocrine functions.
    • These complications are correlated with the total dose and fraction sizes of irradiation and are correlated conversely to the patient's age at the time of treatment. Concomitant chemotherapy increases the risk of toxicity.
    • Verbal IQs and reading skills are affected to a lesser degree than performance IQs or mathematic ability. Personality changes include anxiety, depression, lability, belligerence, hypersexuality, reduced attention span, memory problems, and reduced reasoning ability.
    • GH deficiency with growth retardation and hypothyroidism are much more common than gonadotropin and corticotropin deficiencies.
    • Leukoencephalopathy, hearing loss, and second malignancies (20-y cumulative probability of about 12% for the latter) are increased after cranial irradiation.
Previous
Next

Prognosis

See the list below:

  • Analysis of available data on 5862 patients with germ cell tumors (GCTs) resulted in development of a classification system by the International Germ Cell Collaborative Group (IGCCG).[28] This system categorizes tumors based on histologic type (seminomas have better prognosis than nonseminomas), localization of metastases (retroperitoneal and testicular portend better prognosis than mediastinal and intracranial germ cell tumors), and initial levels of serum AFP, bhCG, and LDH (the higher the tumor markers the worse the effect on survival).
  • Nonseminoma
    • Good prognosis is indicated by all of the following:
      • Testis/retroperitoneal primary
      • No nonpulmonary visceral metastases
      • Good markers - AFP < 1000 ng/mL, bhCG < 1000 IU/L, and LDH < 1.5 X upper limit of normal (N)
      • Includes 56% of nonseminomas, which have a 5-year progression-free survival rate (PFS) of 89% and 5-year survival rate of 92%
    • Intermediate prognosis is indicated by all of the following:
      • Testis/retroperitoneal primary
      • No nonpulmonary visceral metastases
      • Any of AFP >1000 and < 10,000 ng/mL, bhCG >5000 and < 50,000 IU/L, or LDH >1.5 X N and < 10 X N
      • Includes 28% of nonseminomas, which have a 5-year PFS of 75% and 5-year survival rate of 92%
    • Poor prognosis is indicated by any of the following:
      • Mediastinal primary
      • Nonpulmonary visceral metastases
      • Poor markers - Any of AFP >10,000 ng/mL, bhCG >50,000 IU/L, or LDH >10 X N
      • Includes 16% of nonseminomas, which have a 5-year PFS of 41% and 5-year survival rate of 48%
  • Seminoma
    • Good prognosis is indicated by the following:
      • Any primary site
      • No nonpulmonary visceral metastases
      • Normal AFP, any bhCG, any LDH
      • Includes 90% of seminomas, which have a 5-year PFS of 92% and 5-year survival rate of 88%
    • Intermediate prognosis is indicated by the following:
      • Any primary site
      • Nonpulmonary visceral metastases
      • Normal AFP, any bhCG, any LDH
      • Includes 10% of seminomas, which have a 5-year PFS of 67% and 5-year survival rate of 72%
    • Poor prognosis: No patients are classified as having poor prognosis.
  • Ganjoo analyzed the data from 75 patients treated at Indiana University for nonseminomatous mediastinal germ cell tumors (NS-MGCTs) with chemotherapy followed by surgery. Tumor marker elevation prior to or after chemotherapy was not found to be an independent prognostic variable for survival. However, the presence of visceral metastases and especially postchemotherapy pathology were the most important predictors of survival.[29]
  • The Institut Gustave-Roussy prognostic model based on tumor marker levels was not able to classify their group of 38 patients treated for nonseminomatous germ cell tumors accurately. The use of etoposide seemed not to make any difference in survival. Although patients who were able to receive dose-intensive chemotherapy fared better, this did not reach statistical significance. Extrapulmonary metastases remained the sole significant parameter in long-term survival.
  • Patients with mediastinal germ cell tumors (MGCTs) have a poor prognosis owing to at least the following 3 factors: mediastinal germ cell tumors are not as sensitive as other germ cell tumors to chemotherapy, bulky disease increases the risk of poor outcome in the short term owing to respiratory failure, and hematologic malignancies are linked to a very unfavorable prognosis.
Previous
Next

Patient Education

For excellent patient education resources, see eMedicineHealth's patient education article Tailbone (Coccyx) Injury.

Previous
 
Contributor Information and Disclosures
Author

Kush Sachdeva, MD Southern Oncology and Hematology Associates, South Jersey Healthcare, Fox Chase Cancer Center Partner

Disclosure: Nothing to disclose.

Coauthor(s)

Brendan Curti, MD Director, Genitourinary Oncology Research, Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Cancer Center

Brendan Curti, MD is a member of the following medical societies: American College of Physicians, American Society of Clinical Oncology, Oregon Medical Association, Society for Immunotherapy of Cancer

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Prometheus Pharmaceuticals<br/>Received research grant from: Prometheus Pharmaceuticals.

Issam Makhoul, MD Associate Professor, Department of Medicine, Division of Hematology/Oncology, University of Arkansas for Medical Sciences

Issam Makhoul, MD is a member of the following medical societies: American Society of Clinical Oncology, American Society of Hematology

Disclosure: Nothing to disclose.

Bagi RP Jana, MD Associate Professor of Medicine (Genitourinary Oncology), Division of Hematology and Oncology, University of Texas Medical Branch

Bagi RP Jana, MD is a member of the following medical societies: American Cancer Society, American Medical Association, SWOG, American Society of Clinical Oncology

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Jules E Harris, MD, FACP, FRCPC Clinical Professor of Medicine, Section of Hematology/Oncology, University of Arizona College of Medicine, Arizona Cancer Center

Jules E Harris, MD, FACP, FRCPC is a member of the following medical societies: American Association for the Advancement of Science, American Society of Hematology, Central Society for Clinical and Translational Research, American Society of Clinical Oncology

Disclosure: Nothing to disclose.

Additional Contributors

Robert C Shepard, MD, FACP Associate Professor of Medicine in Hematology and Oncology at University of North Carolina at Chapel Hill; Vice President of Scientific Affairs, Therapeutic Expertise, Oncology, at PRA International

Robert C Shepard, MD, FACP is a member of the following medical societies: American Association for Cancer Research, American Association for Physician Leadership, European Society for Medical Oncology, Association of Clinical Research Professionals, American Federation for Clinical Research, Eastern Cooperative Oncology Group, Society for Immunotherapy of Cancer, American Medical Informatics Association, American College of Physicians, American Federation for Medical Research, American Medical Association, American Society of Hematology, Massachusetts Medical Society

Disclosure: Nothing to disclose.

References
  1. Hasle H, Mellemgaard A, Nielsen J, et al. Cancer incidence in men with Klinefelter syndrome. Br J Cancer. 1995 Feb. 71(2):416-20. [Medline].

  2. Hasle H, Jacobsen BB, Asschenfeldt P, et al. Mediastinal germ cell tumour associated with Klinefelter syndrome. A report of case and review of the literature. Eur J Pediatr. 1992 Oct. 151(10):735-9. [Medline].

  3. Bosl GJ, Ilson DH, Rodriguez E, et al. Clinical relevance of the i(12p) marker chromosome in germ cell tumors. J Natl Cancer Inst. 1994 Mar 2. 86(5):349-55. [Medline].

  4. Hartmann JT, Nichols CR, Droz JP, et al. Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors. J Natl Cancer Inst. 2000 Jan 5. 92(1):54-61. [Medline].

  5. Iwato M, Tachibana O, Tohma Y, et al. Alterations of the INK4a/ARF locus in human intracranial germ cell tumors. Cancer Res. 2000 Apr 15. 60(8):2113-5. [Medline].

  6. Dueland S, Stenwig AE, Heilo A, et al. Treatment and outcome of patients with extragonadal germ cell tumours--the Norwegian Radium Hospital's experience 1979-94. Br J Cancer. 1998. 77(2):329-35. [Medline].

  7. Takeda S, Miyoshi S, Ohta M, et al. Primary germ cell tumors in the mediastinum: a 50-year experience at a single Japanese institution. Cancer. 2003 Jan 15. 97(2):367-76. [Medline].

  8. Rusner C, Trabert B, Katalinic A, Kieschke J, Emrich K, Stang A. Incidence patterns and trends of malignant gonadal and extragonadal germ cell tumors in Germany, 1998-2008. Cancer Epidemiol. 2013 Aug. 37(4):370-3. [Medline].

  9. Albany C, Einhorn LH. Extragonadal germ cell tumors: clinical presentation and management. Curr Opin Oncol. 2013 May. 25(3):261-5. [Medline].

  10. Ganslandt O, Buchfelder M, Grabenbauer GG. Primary spinal germinoma in a patient with concomitant Klinefelter's syndrome. Br J Neurosurg. 2000 Jun. 14(3):252-5. [Medline].

  11. Albers P, Bender H, Yilmaz H, et al. Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors. Urology. 1999 Apr. 53(4):808-11. [Medline].

  12. Cremerius U, Effert PJ, Adam G, et al. FDG PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med. 1998 May. 39(5):815-22. [Medline].

  13. Stephens AW, Gonin R, Hutchins GD, et al. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol. 1996 May. 14(5):1637-41. [Medline].

  14. De Santis M, Becherer A, Bokemeyer C, et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol. 2004 Mar 15. 22(6):1034-9. [Medline].

  15. Womeldorph CM, Zalupski MM, Knoepp SM, Soltani M, Elmunzer BJ. Retroperitoneal germ cell tumor diagnosed by endoscopic ultrasound-guided fine needle aspiration. World J Gastrointest Oncol. 2010 Dec 15. 2(12):443-5. [Medline]. [Full Text].

  16. Cao D, Liu A, Wang F, Allan RW, Mei K, Peng Y, et al. RNA-binding protein LIN28 is a marker for primary extragonadal germ cell tumors: an immunohistochemical study of 131 cases. Mod Pathol. 2011 Feb. 24(2):288-96. [Medline].

  17. Fizazi K, Culine S, Droz JP, et al. Primary mediastinal nonseminomatous germ cell tumors: results of modern therapy including cisplatin-based chemotherapy. J Clin Oncol. 1998 Feb. 16(2):725-32. [Medline].

  18. Samuels ML, Johnson DE, Holoye PY, et al. Large-dose bleomycin therapy and pulmonary toxicity. A possible role of prior radiotherapy. JAMA. 1976 Mar 15. 235(11):1117-20. [Medline].

  19. Walsh GL, Taylor GD, Nesbitt JC, et al. Intensive chemotherapy and radical resections for primary nonseminomatous mediastinal germ cell tumors. Ann Thorac Surg. 2000 Feb. 69(2):337-43; discussion 343-4. [Medline].

  20. Saxman SB, Nichols CR, Einhorn LH. Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: the Indiana University experience. J Clin Oncol. 1994 Jul. 12(7):1390-3. [Medline].

  21. Calaminus G, Bamberg M, Baranzelli MC, et al. Intracranial germ cell tumors: a comprehensive update of the European data. Neuropediatrics. 1994 Feb. 25(1):26-32. [Medline].

  22. Balmaceda C, Heller G, Rosenblum M, et al. Chemotherapy without irradiation--a novel approach for newly diagnosed CNS germ cell tumors: results of an international cooperative trial. The First International Central Nervous System Germ Cell Tumor Study. J Clin Oncol. 1996 Nov. 14(11):2908-15. [Medline].

  23. Pectasides D, Aravantinos G, Visvikis A, et al. Platinum-based chemotherapy of primary extragonadal germ cell tumours: the Hellenic Cooperative Oncology Group experience. Oncology. 1999 Jul. 57(1):1-9. [Medline].

  24. Nichols CR, Fox EP. Extragonadal and pediatric germ cell tumors. Hematol Oncol Clin North Am. 1991 Dec. 5(6):1189-209. [Medline].

  25. Andre F, Fizazi K, Culine S, et al. The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Eur J Cancer. 2000 Jul. 36(11):1389-94. [Medline].

  26. Gunes S, Varon J, Walsh G. Mediastinal teratoma presenting as massive hemoptysis in an adult. J Emerg Med. 1997 May-Jun. 15(3):313-6. [Medline].

  27. Weijl NI, Rutten MF, Zwinderman AH, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol. 2000 May. 18(10):2169-78. [Medline].

  28. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor- based staging system for metastatic germ cell cancers. J Clin Oncol. 1997 Feb. 15(2):594-603. [Medline].

  29. Ganjoo KN, Rieger KM, Kesler KA, et al. Results of modern therapy for patients with mediastinal nonseminomatous germ cell tumors. Cancer. 2000 Mar 1. 88(5):1051-6. [Medline].

  30. Abeloff MD, Armitage JO, Niederhuber J, et al. Clinical Oncology. 4nd ed. New York: Churchill Livingstone; 2008.

  31. Adebonojo SA, Nicola ML. Teratoid tumors of the mediastinum. Am Surg. 1976 May. 42(5):361-5. [Medline].

  32. Arai K, Ohta S, Suzuki M, et al. Primary immature mediastinal teratoma in adulthood. Eur J Surg Oncol. 1997 Feb. 23(1):64-7. [Medline].

  33. Baranzelli MC, Patte C, Bouffet E, et al. Nonmetastatic intracranial germinoma: the experience of the French Society of Pediatric Oncology. Cancer. 1997 Nov 1. 80(9):1792-7. [Medline].

  34. Bokemeyer C, Droz JP, Horwich A, et al. Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome. Cancer. 2001 Apr 1. 91(7):1394-401. [Medline].

  35. Bokemeyer C, Nichols CR, Droz JP, et al. Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol. 2002 Apr 1. 20(7):1864-73. [Medline].

  36. Broun ER, Nichols CR, Einhorn LH, et al. Salvage therapy with high-dose chemotherapy and autologous bone marrow support in the treatment of primary nonseminomatous mediastinal germ cell tumors. Cancer. 1991 Oct 1. 68(7):1513-5. [Medline].

  37. Böhle A, Studer UE, Sonntag RW, et al. Primary or secondary extragonadal germ cell tumors?. J Urol. 1986 May. 135(5):939-43. [Medline].

  38. Chaganti RS, Houldsworth J. Genetics and biology of adult human male germ cell tumors. Cancer Res. 2000 Mar 15. 60(6):1475-82. [Medline].

  39. Chaganti RS, Rodriguez E, Mathew S. Origin of adult male mediastinal germ-cell tumours. Lancet. 1994 May 7. 343(8906):1130-2. [Medline].

  40. Cheng L. Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry. Cancer. 2004 Nov 1. 101(9):2006-10. [Medline].

  41. Christmas TJ, Doherty AP, Rustin GJ, et al. Primary retroperitoneal germ cell tumours: excision via a thoracoabdominal extraperitoneal approach. Br J Surg. 1997 Jul. 84(7):1022-5. [Medline].

  42. Comiter CV, Renshaw AA, Benson CB, et al. Burned-out primary testicular cancer: sonographic and pathological characteristics. J Urol. 1996 Jul. 156(1):85-8. [Medline].

  43. Crossen JR, Garwood D, Glatstein E, et al. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol. 1994 Mar. 12(3):627-42. [Medline].

  44. Daugaard G, Rorth M, von der Maase H, et al. Management of extragonadal germ-cell tumors and the significance of bilateral testicular biopsies. Ann Oncol. 1992 Apr. 3(4):283-9. [Medline].

  45. Davis RD Jr, Oldham HN Jr, Sabiston DC Jr. Primary cysts and neoplasms of the mediastinum: recent changes in clinical presentation, methods of diagnosis, management, and results. Ann Thorac Surg. 1987 Sep. 44(3):229-37. [Medline].

  46. DeVita VT, Lawrence T,S Rosenberg SA, eds. Cancer, Principles and Practice of Oncology. 8th ed. Philadelphia: Lippincott, Williams & Wilkins; 2008.

  47. Donadio AC, Motzer RJ, Bajorin DF, et al. Chemotherapy for teratoma with malignant transformation. J Clin Oncol. 2003 Dec 1. 21(23):4285-91. [Medline].

  48. Droz JP, Horwich A. Extragonadal Germ Cell Tumors. Comprehensive Textbook of Genitourinary Oncology, Vogelzang, NJ, Scardino, PT, Shipley, WU, Doffey, DS (Eds). Second Edition. New York: Lippincott Williams and Wilkins; 2005.

  49. Duchesne GM, Stenning SP, Aass N, et al. Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working Party. Eur J Cancer. 1997 May. 33(6):829-35. [Medline].

  50. Duffner PK, Cohen ME, Thomas PR, et al. The long-term effects of cranial irradiation on the central nervous system. Cancer. 1985 Oct 1. 56(7 Suppl):1841-6. [Medline].

  51. Dulmet EM, Macchiarini P, Suc B, et al. Germ cell tumors of the mediastinum. A 30-year experience. Cancer. 1993 Sep 15. 72(6):1894-901. [Medline].

  52. Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol. 1989 Mar. 7(3):387-91. [Medline].

  53. Feo CF, Chironi G, Porcu A, et al. Videothoracoscopic removal of a mediastinal teratoma. Am Surg. 1997 May. 63(5):459-61. [Medline].

  54. Glenn OA, Barkovich AJ. Intracranial germ cell tumors: a comprehensive review of proposed embryologic derivation. Pediatr Neurosurg. 1996. 24(5):242-51. [Medline].

  55. Gordon MS, Battiato LA, Finch D, et al. Dramatic response of teratoma-associated non--germ-cell cancer with all-trans retinoic acid in a patient with nonseminomatous germ cell tumor. Am J Clin Oncol. 2001 Jun. 24(3):269-71. [Medline].

  56. Hailemariam S, Engeler DS, Bannwart F, et al. Primary mediastinal germ cell tumor with intratubular germ cell neoplasia of the testis--further support for germ cell origin of these tumors: a case report. Cancer. 1997 Mar 1. 79(5):1031-6. [Medline].

  57. Hainsworth JD, Greco FA. Extragonadal germ cell tumors and unrecognized germ cell tumors. Semin Oncol. 1992 Apr. 19(2):119-27. [Medline].

  58. Hainsworth JD, Greco FA. Poorly differentiated carcinoma and germ cell tumors. Hematol Oncol Clin North Am. 1991 Dec. 5(6):1223-31. [Medline].

  59. Hartmann JT, Einhorn L, Nichols CR, et al. Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis. J Clin Oncol. 2001 Mar 15. 19(6):1641-8. [Medline].

  60. Hartmann JT, Fossa SD, Nichols CR, et al. Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors. J Natl Cancer Inst. 2001 Nov 21. 93(22):1733-8. [Medline].

  61. Hartmann JT, Nichols CR, Droz JP, et al. Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. Ann Oncol. 2002 Jul. 13(7):1017-28. [Medline].

  62. Hartmann JT, Nichols CR, Droz JP, et al. The relative risk of second nongerminal malignancies in patients with extragonadal germ cell tumors. Cancer. 2000 Jun 1. 88(11):2629-35. [Medline].

  63. Heinonen K, Rao PN, Slack JL, et al. Isochromosome 12p in two cases of acute myeloid leukaemia without evidence of germ cell tumour. Br J Haematol. 1996 Jun. 93(3):677-80. [Medline].

  64. Hidalgo M, Paz-Ares L, Rivera F, et al. Mediastinal non-seminomatous germ cell tumours (MNSGCT) treated with cisplatin-based combination chemotherapy. Ann Oncol. 1997 Jun. 8(6):555-9. [Medline].

  65. Hooda BS, Finlay JL. Recent advances in the diagnosis and treatment of central nervous system germ-cell tumours. Curr Opin Neurol. 1999 Dec. 12(6):693-6. [Medline].

  66. Horton Z, Schlatter M, Schultz S. Pediatric germ cell tumors. Surg Oncol. 2007 Nov. 16(3):205-13. [Medline].

  67. Horwich A, Paluchowska B, Norman A, et al. Residual mass following chemotherapy of seminoma. Ann Oncol. 1997 Jan. 8(1):37-40. [Medline].

  68. Iczkowski KA, Butler SL, Shanks JH, et al. Trials of new germ cell immunohistochemical stains in 93 extragonadal and metastatic germ cell tumors. Hum Pathol. 2008 Feb. 39(2):275-81. [Medline].

  69. Jacob R, Ramadas K, Jyothirmayi R, et al. Extragonadal germ-cell tumors: a ten-year experience. Am J Clin Oncol. 1998 Apr. 21(2):198-202. [Medline].

  70. Knapp RH, Hurt RD, Payne WS, et al. Malignant germ cell tumors of the mediastinum. J Thorac Cardiovasc Surg. 1985 Jan. 89(1):82-9. [Medline].

  71. Knappe UJ, Bentele K, Horstmann M, et al. Treatment and long-term outcome of pineal nongerminomatous germ cell tumors. Pediatr Neurosurg. 1998 May. 28(5):241-5. [Medline].

  72. Kumano M, Miyake H, Hara I, et al. First-line high-dose chemotherapy combined with peripheral blood stem cell transplantation for patients with advanced extragonadal germ cell tumors. Int J Urol. 2007 Apr. 14(4):336-8. [Medline].

  73. Ladanyi M, Samaniego F, Reuter VE, et al. Cytogenetic and immunohistochemical evidence for the germ cell origin of a subset of acute leukemias associated with mediastinal germ cell tumors. J Natl Cancer Inst. 1990 Feb 7. 82(3):221-7. [Medline].

  74. Lewis BD, Hurt RD, Payne WS, et al. Benign teratomas of the mediastinum. J Thorac Cardiovasc Surg. 1983 Nov. 86(5):727-31. [Medline].

  75. Marina N, London WB, Frazier AL, et al. Prognostic factors in children with extragonadal malignant germ cell tumors: a pediatric intergroup study. J Clin Oncol. 2006 Jun 1. 24(16):2544-8. [Medline].

  76. McAleer JJ, Nicholls J, Horwich A. Does extragonadal presentation impart a worse prognosis to abdominal germ-cell tumours?. Eur J Cancer. 1992. 28A(4-5):825-8. [Medline].

  77. McKenney JK, Heerema-McKenney A, Rouse RV. Extragonadal germ cell tumors: a review with emphasis on pathologic features, clinical prognostic variables, and differential diagnostic considerations. Adv Anat Pathol. 2007 Mar. 14(2):69-92. [Medline].

  78. Medical Economics Staff. Physician Desk Reference. 54th ed. Medical Economics Company; 2000.

  79. Merchant TE, Sherwood SH, Mulhern RK, et al. CNS germinoma: disease control and long-term functional outcome for 12 children treated with craniospinal irradiation. Int J Radiat Oncol Biol Phys. 2000 Mar 15. 46(5):1171-6. [Medline].

  80. Moeller KH, Rosado-de-Christenson ML, Templeton PA. Mediastinal mature teratoma: imaging features. AJR Am J Roentgenol. 1997 Oct. 169(4):985-90. [Medline].

  81. Moran CA, Suster S. Primary germ cell tumors of the mediastinum: I. Analysis of 322 cases with special emphasis on teratomatous lesions and a proposal for histopathologic classification and clinical staging. Cancer. 1997 Aug 15. 80(4):681-90. [Medline].

  82. Moran CA, Suster S, Koss MN. Primary germ cell tumors of the mediastinum: III. Yolk sac tumor, embryonal carcinoma, choriocarcinoma, and combined nonteratomatous germ cell tumors of the mediastinum--a clinicopathologic and immunohistochemical study of 64 cases. Cancer. 1997 Aug 15. 80(4):699-707. [Medline].

  83. Moran CA, Suster S, Przygodzki RM, et al. Primary germ cell tumors of the mediastinum: II. Mediastinal seminomas--a clinicopathologic and immunohistochemical study of 120 cases. Cancer. 1997 Aug 15. 80(4):691-8. [Medline].

  84. Mordecai D, Shaw RJ, Fisher PG, et al. Case study: suprasellar germinoma presenting with psychotic and obsessive-compulsive symptoms. J Am Acad Child Adolesc Psychiatry. 2000 Jan. 39(1):116-9. [Medline].

  85. Motzer R, Bosl G, Heelan R, et al. Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. J Clin Oncol. 1987 Jul. 5(7):1064-70. [Medline].

  86. Motzer RJ, Amsterdam A, Prieto V, et al. Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol. 1998 Jan. 159(1):133-8. [Medline].

  87. Motzer RJ, Rodriguez E, Reuter VE, et al. Genetic analysis as an aid in diagnosis for patients with midline carcinomas of uncertain histologies. J Natl Cancer Inst. 1991 Mar 6. 83(5):341-6. [Medline].

  88. Motzer RJ, Rodriguez E, Reuter VE, et al. Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. J Clin Oncol. 1995 Jan. 13(1):274-82. [Medline].

  89. Nichols CR, Roth BJ, Heerema N, et al. Hematologic neoplasia associated with primary mediastinal germ-cell tumors. N Engl J Med. 1990 May 17. 322(20):1425-9. [Medline].

  90. Oosterhuis JW, Stoop H, Honecker F, et al. Why human extragonadal germ cell tumours occur in the midline of the body: old concepts, new perspectives. Int J Androl. 2007 Aug. 30(4):256-63; discussion 263-4. [Medline].

  91. Orazi A, Neiman RS, Ulbright TM, et al. Hematopoietic precursor cells within the yolk sac tumor component are the source of secondary hematopoietic malignancies in patients with mediastinal germ cell tumors. Cancer. 1993 Jun 15. 71(12):3873-81. [Medline].

  92. Parada D, Pena KB, Moreira O, et al. Extragonadal retroperitoneal germ cell tumor: primary versus metastases?. Arch Esp Urol. 2007 Jul-Aug. 60(6):713-9. [Medline].

  93. Pectasides D, Valavanis C, Nikolaou M, et al. Molecular markers in extragonadal germ cell tumours: a matched case-control study. Histopathology. 2007 Feb. 50(3):394-6. [Medline].

  94. Perry MC, ed. The Chemotherapy Source Book. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2001.

  95. Polansky SM, Barwick KW, Ravin CE. Primary mediastinal seminoma. AJR Am J Roentgenol. 1979 Jan. 132(1):17-21. [Medline].

  96. Puc HS, Heelan R, Mazumdar M, et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol. 1996 Feb. 14(2):454-60. [Medline].

  97. Rescorla FJ. Pediatric germ cell tumors. Semin Surg Oncol. 1999 Mar. 16(2):144-58. [Medline].

  98. Richardson RL, Schoumacher RA, Fer MF, et al. The unrecognized extragonadal germ cell cancer syndrome. Ann Intern Med. 1981 Feb. 94(2):181-6. [Medline].

  99. Rothman J, Greenberg RE, Jaffe WI. Nonseminomatous germ cell tumor of the testis 9 years after a germ cell tumor of the pineal gland: case report and review of the literature. Can J Urol. 2008 Jun. 15(3):4122-4. [Medline].

  100. Sawamura Y, Ikeda JL, Tada M, et al. Salvage therapy for recurrent germinomas in the central nervous system. Br J Neurosurg. 1999 Aug. 13(4):376-81. [Medline].

  101. Schmoll HJ, Souchon R, Krege S, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol. 2004 Sep. 15(9):1377-99. [Medline].

  102. Schneider BP, Kesler KA, Brooks JA, et al. Outcome of patients with residual germ cell or non-germ cell malignancy after resection of primary mediastinal nonseminomatous germ cell cancer. J Clin Oncol. 2004 Apr 1. 22(7):1195-200. [Medline].

  103. Schultz SM, Einhorn LH, Conces DJ Jr, et al. Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol. 1989 Oct. 7(10):1497-503. [Medline].

  104. Shivdasani, RA,, Kantoff, PW. Extragonadal germ cell tumors. Raghavan, D, Scher, HI, Leibel, SA, Lange, P (Eds). Principles and Practice of Genitourinary Oncology. Lippincott-Raven: Philadelphia; 1997.

  105. Uchiyama M, Kantoff PW, Kaplan WD. Gallium-67-citrate imaging in extragonadal and gonadal seminomas: relationship to radiologic findings. J Nucl Med. 1994 Oct. 35(10):1624-30. [Medline].

  106. Vuky J, Bains M, Bacik J, et al. Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum. J Clin Oncol. 2001 Feb 1. 19(3):682-8. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.